Adam Graham Stewart, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Enterobacteriaceae Infections | 5 | 2022 | 190 | 2.380 |
Why?
|
Bacteremia | 11 | 2024 | 986 | 2.240 |
Why?
|
beta-Lactamases | 9 | 2023 | 307 | 2.020 |
Why?
|
Anti-Bacterial Agents | 25 | 2024 | 7477 | 1.910 |
Why?
|
Sepsis | 9 | 2024 | 2608 | 1.520 |
Why?
|
Drug Resistance, Multiple, Bacterial | 5 | 2020 | 591 | 1.510 |
Why?
|
Australia | 14 | 2024 | 1265 | 1.500 |
Why?
|
Gram-Negative Bacterial Infections | 4 | 2020 | 238 | 1.490 |
Why?
|
Enterobacteriaceae | 3 | 2021 | 161 | 1.400 |
Why?
|
Microbial Sensitivity Tests | 15 | 2023 | 1967 | 1.340 |
Why?
|
Mycoses | 2 | 2023 | 386 | 1.260 |
Why?
|
Skin Diseases, Bacterial | 2 | 2019 | 65 | 1.190 |
Why?
|
Streptococcal Infections | 2 | 2024 | 619 | 1.180 |
Why?
|
Antifungal Agents | 5 | 2024 | 761 | 1.160 |
Why?
|
Queensland | 8 | 2024 | 53 | 1.020 |
Why?
|
Gram-Negative Bacteria | 5 | 2023 | 275 | 1.000 |
Why?
|
Fusobacterium | 1 | 2024 | 56 | 0.950 |
Why?
|
Viridans Streptococci | 1 | 2024 | 16 | 0.950 |
Why?
|
Blood Donors | 2 | 2024 | 343 | 0.950 |
Why?
|
Fusobacterium Infections | 1 | 2024 | 54 | 0.930 |
Why?
|
beta-Lactam Resistance | 1 | 2024 | 79 | 0.900 |
Why?
|
Scedosporium | 1 | 2023 | 10 | 0.880 |
Why?
|
Organ Transplantation | 2 | 2024 | 1176 | 0.880 |
Why?
|
Flavobacteriaceae Infections | 1 | 2023 | 1 | 0.870 |
Why?
|
Chryseobacterium | 1 | 2023 | 5 | 0.860 |
Why?
|
Fungemia | 1 | 2023 | 57 | 0.850 |
Why?
|
Escherichia coli | 4 | 2023 | 4214 | 0.830 |
Why?
|
Thyroiditis, Subacute | 1 | 2022 | 11 | 0.810 |
Why?
|
Arthritis, Reactive | 1 | 2022 | 20 | 0.800 |
Why?
|
Urethritis | 1 | 2022 | 30 | 0.790 |
Why?
|
Mycoplasma genitalium | 1 | 2022 | 13 | 0.790 |
Why?
|
Cefotetan | 1 | 2021 | 6 | 0.770 |
Why?
|
Mycoplasma Infections | 1 | 2022 | 120 | 0.770 |
Why?
|
Thyrotoxicosis | 1 | 2022 | 85 | 0.750 |
Why?
|
Cryptococcosis | 1 | 2021 | 103 | 0.720 |
Why?
|
Cryptococcus neoformans | 1 | 2021 | 121 | 0.720 |
Why?
|
Hyperammonemia | 1 | 2021 | 80 | 0.710 |
Why?
|
Granulomatous Disease, Chronic | 1 | 2021 | 175 | 0.700 |
Why?
|
Brain Abscess | 1 | 2021 | 123 | 0.690 |
Why?
|
Klebsiella pneumoniae | 2 | 2022 | 253 | 0.690 |
Why?
|
Catheter-Related Infections | 1 | 2023 | 275 | 0.690 |
Why?
|
Klebsiella Infections | 1 | 2021 | 146 | 0.680 |
Why?
|
Patient Isolation | 1 | 2020 | 101 | 0.660 |
Why?
|
Listeria monocytogenes | 1 | 2021 | 246 | 0.650 |
Why?
|
Q Fever | 1 | 2019 | 38 | 0.640 |
Why?
|
Mycobacterium avium Complex | 1 | 2019 | 66 | 0.630 |
Why?
|
Drug Resistance, Fungal | 3 | 2024 | 78 | 0.620 |
Why?
|
Streptococcus agalactiae | 1 | 2020 | 337 | 0.620 |
Why?
|
Cephalosporins | 5 | 2023 | 200 | 0.620 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2019 | 82 | 0.610 |
Why?
|
Staphylococcal Infections | 4 | 2023 | 1398 | 0.590 |
Why?
|
Immunocompromised Host | 1 | 2023 | 863 | 0.590 |
Why?
|
Typhus, Epidemic Louse-Borne | 1 | 2017 | 2 | 0.590 |
Why?
|
Escherichia coli Infections | 1 | 2021 | 524 | 0.560 |
Why?
|
Drug Resistance, Bacterial | 3 | 2022 | 1063 | 0.560 |
Why?
|
Tick-Borne Diseases | 1 | 2017 | 37 | 0.560 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 837 | 0.550 |
Why?
|
Leukemia | 1 | 2023 | 1519 | 0.480 |
Why?
|
Urinary Tract Infections | 1 | 2020 | 804 | 0.450 |
Why?
|
Anti-Infective Agents | 1 | 2021 | 983 | 0.440 |
Why?
|
beta-Lactams | 1 | 2015 | 158 | 0.440 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2020 | 843 | 0.430 |
Why?
|
Brain Diseases | 1 | 2021 | 1554 | 0.400 |
Why?
|
Diarrhea | 1 | 2019 | 1320 | 0.400 |
Why?
|
Aspergillus | 2 | 2023 | 95 | 0.400 |
Why?
|
Osteomyelitis | 1 | 2015 | 408 | 0.370 |
Why?
|
Drug Monitoring | 2 | 2022 | 964 | 0.350 |
Why?
|
Pseudomonas aeruginosa | 3 | 2022 | 1276 | 0.330 |
Why?
|
Endocarditis, Bacterial | 2 | 2024 | 436 | 0.320 |
Why?
|
Molecular Epidemiology | 2 | 2021 | 473 | 0.310 |
Why?
|
Humans | 49 | 2024 | 768166 | 0.310 |
Why?
|
Terminal Care | 1 | 2020 | 1770 | 0.300 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1942 | 0.280 |
Why?
|
Candidiasis, Invasive | 1 | 2024 | 26 | 0.240 |
Why?
|
Blood Safety | 1 | 2024 | 16 | 0.230 |
Why?
|
Echinocandins | 1 | 2024 | 54 | 0.230 |
Why?
|
Ceftazidime | 2 | 2022 | 57 | 0.230 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2019 | 2442 | 0.230 |
Why?
|
Candidemia | 1 | 2024 | 40 | 0.230 |
Why?
|
Candida | 1 | 2024 | 173 | 0.220 |
Why?
|
Clavulanic Acid | 1 | 2023 | 19 | 0.220 |
Why?
|
Cefixime | 1 | 2023 | 13 | 0.220 |
Why?
|
Ureaplasma Infections | 1 | 2023 | 25 | 0.220 |
Why?
|
Mediastinitis | 1 | 2023 | 49 | 0.210 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5717 | 0.210 |
Why?
|
Cross Infection | 2 | 2022 | 1426 | 0.210 |
Why?
|
Sphingomonas | 1 | 2022 | 6 | 0.200 |
Why?
|
Morganella morganii | 1 | 2022 | 9 | 0.200 |
Why?
|
Klebsiella | 1 | 2022 | 49 | 0.200 |
Why?
|
Shewanella | 1 | 2022 | 12 | 0.200 |
Why?
|
Azoles | 1 | 2022 | 23 | 0.200 |
Why?
|
Donor Selection | 1 | 2024 | 240 | 0.200 |
Why?
|
Clinical Trials as Topic | 3 | 2023 | 8054 | 0.190 |
Why?
|
Cefoxitin | 1 | 2021 | 36 | 0.190 |
Why?
|
Achromobacter | 1 | 2020 | 8 | 0.180 |
Why?
|
Macrolides | 1 | 2022 | 204 | 0.180 |
Why?
|
Saudi Arabia | 1 | 2021 | 212 | 0.180 |
Why?
|
Fluoroquinolones | 1 | 2022 | 309 | 0.180 |
Why?
|
Lebanon | 1 | 2021 | 245 | 0.170 |
Why?
|
Singapore | 1 | 2021 | 300 | 0.170 |
Why?
|
Adult | 14 | 2024 | 223646 | 0.170 |
Why?
|
Spain | 1 | 2021 | 485 | 0.170 |
Why?
|
Granulocytes | 1 | 2021 | 551 | 0.160 |
Why?
|
Cytomegalovirus | 1 | 2023 | 753 | 0.160 |
Why?
|
Italy | 1 | 2021 | 856 | 0.160 |
Why?
|
Sigmoidoscopy | 1 | 2019 | 150 | 0.160 |
Why?
|
Drug Resistance, Microbial | 1 | 2021 | 830 | 0.150 |
Why?
|
Endocarditis | 1 | 2022 | 352 | 0.150 |
Why?
|
Middle Aged | 11 | 2024 | 223492 | 0.150 |
Why?
|
Arachnid Vectors | 1 | 2017 | 24 | 0.150 |
Why?
|
Rickettsia | 1 | 2017 | 11 | 0.150 |
Why?
|
Incidence | 3 | 2024 | 21538 | 0.140 |
Why?
|
Blood Transfusion | 1 | 2024 | 1309 | 0.140 |
Why?
|
Azabicyclo Compounds | 3 | 2022 | 68 | 0.140 |
Why?
|
Health Literacy | 1 | 2022 | 466 | 0.140 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 1049 | 0.140 |
Why?
|
Virulence Factors | 1 | 2020 | 502 | 0.140 |
Why?
|
Aged | 10 | 2024 | 171504 | 0.140 |
Why?
|
Young Adult | 6 | 2024 | 60066 | 0.130 |
Why?
|
Treatment Failure | 1 | 2023 | 2661 | 0.130 |
Why?
|
Carbapenems | 3 | 2022 | 125 | 0.130 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 1737 | 0.130 |
Why?
|
Male | 14 | 2024 | 364719 | 0.130 |
Why?
|
Thienamycins | 1 | 2015 | 29 | 0.130 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 704 | 0.130 |
Why?
|
Amikacin | 1 | 2015 | 48 | 0.130 |
Why?
|
Fosfomycin | 1 | 2015 | 26 | 0.120 |
Why?
|
Enterobacter cloacae | 1 | 2015 | 25 | 0.120 |
Why?
|
Neoplasms | 1 | 2024 | 22371 | 0.120 |
Why?
|
Geography | 1 | 2017 | 652 | 0.120 |
Why?
|
Staphylococcus aureus | 4 | 2024 | 1430 | 0.120 |
Why?
|
Staphylococcus epidermidis | 1 | 2015 | 121 | 0.120 |
Why?
|
Scleroderma, Systemic | 1 | 2019 | 346 | 0.120 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2020 | 621 | 0.120 |
Why?
|
Colectomy | 1 | 2019 | 696 | 0.110 |
Why?
|
Travel | 1 | 2019 | 805 | 0.110 |
Why?
|
Female | 10 | 2024 | 397192 | 0.100 |
Why?
|
Infection Control | 1 | 2020 | 985 | 0.100 |
Why?
|
Phylogeny | 1 | 2020 | 2843 | 0.100 |
Why?
|
Feces | 1 | 2019 | 1511 | 0.100 |
Why?
|
Intensive Care Units | 2 | 2023 | 3800 | 0.100 |
Why?
|
Retrospective Studies | 6 | 2024 | 81762 | 0.100 |
Why?
|
Antitubercular Agents | 1 | 2020 | 1397 | 0.100 |
Why?
|
Echocardiography | 1 | 2024 | 5047 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2023 | 3073 | 0.090 |
Why?
|
Calcinosis | 1 | 2019 | 1481 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2022 | 59629 | 0.080 |
Why?
|
Drug Interactions | 2 | 2024 | 1419 | 0.080 |
Why?
|
Bacterial Proteins | 1 | 2021 | 3840 | 0.070 |
Why?
|
Risk Factors | 3 | 2024 | 74944 | 0.070 |
Why?
|
Adolescent | 4 | 2022 | 89169 | 0.060 |
Why?
|
Soft Tissue Infections | 1 | 2007 | 168 | 0.060 |
Why?
|
Drug Combinations | 2 | 2022 | 2089 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 13014 | 0.060 |
Why?
|
Half-Life | 1 | 2024 | 651 | 0.050 |
Why?
|
Mycoplasma hominis | 1 | 2023 | 10 | 0.050 |
Why?
|
Ureaplasma | 1 | 2023 | 59 | 0.050 |
Why?
|
Ureaplasma urealyticum | 1 | 2023 | 39 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2015 | 3858 | 0.050 |
Why?
|
Hospitalization | 1 | 2023 | 10840 | 0.050 |
Why?
|
Consent Forms | 1 | 2022 | 55 | 0.050 |
Why?
|
Pasteurella | 1 | 2022 | 6 | 0.050 |
Why?
|
DNA Gyrase | 1 | 2022 | 86 | 0.050 |
Why?
|
Borinic Acids | 1 | 2021 | 2 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2024 | 13676 | 0.050 |
Why?
|
Colistin | 1 | 2021 | 46 | 0.050 |
Why?
|
Carboxylic Acids | 1 | 2021 | 91 | 0.040 |
Why?
|
Animals | 4 | 2024 | 169246 | 0.040 |
Why?
|
Acinetobacter baumannii | 1 | 2021 | 123 | 0.040 |
Why?
|
Fungi | 1 | 2022 | 345 | 0.040 |
Why?
|
Infant | 1 | 2020 | 36535 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2024 | 4860 | 0.030 |
Why?
|
Focus Groups | 1 | 2022 | 1460 | 0.030 |
Why?
|
Informed Consent | 1 | 2022 | 1010 | 0.030 |
Why?
|
Triazoles | 1 | 2021 | 904 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2022 | 65371 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2359 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 54926 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2024 | 3780 | 0.030 |
Why?
|
Qualitative Research | 1 | 2022 | 3140 | 0.020 |
Why?
|
Mycobacterium fortuitum | 1 | 2007 | 6 | 0.020 |
Why?
|
Mycobacterium ulcerans | 1 | 2007 | 9 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8741 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5349 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10399 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15454 | 0.010 |
Why?
|
Prognosis | 1 | 2024 | 30010 | 0.010 |
Why?
|
Child | 2 | 2022 | 80917 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 30238 | 0.010 |
Why?
|